24 November 2015 - The U.S. FDA today approved Portrazza (necitumumab) for use in combination with two forms of chemotherapy to treat patients with advanced (metastatic) squamous non-small cell lung cancer who have not previously received medication specifically for treating their advanced lung cancer.

For more details, go to: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm474131.htm